Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.

JAMA dermatology - 1 Jul 2016

Arakawa Akiko, Ruzicka Thomas, Prinz Jörg C

Abstract excerpt

IMPORTANCE: Generalized pustular psoriasis von Zumbusch type (GPP) is the most severe manifestation of psoriasis. The etiology of GPP is only partially understood, and GPP lacks approved treatments. Loss-of-function mutations in the interleukin 36 (IL-36) receptor antagonist (IL36RN), an inhibitor of innate immune activation in the skin, and therapeutic efficacy of IL-1 blockade in a subset of patients with GPP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatologic Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukin-12

Share to Interleukin-23

Share to Interleukins

Share to Mutation

Share to Psoriasis

Share to Remission Induction

Source

Identifiers

PMID: 27096382
DOI: 10.1001/jamadermatol.2016.0751

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.PMID 27096382Read ↗

Generalized pustular psoriasis: immunological mechanisms, genetics, and emerging therapeutics.Semantic proximity Read ↗

Spesolimab for generalized pustular psoriasis: a prospective study with a 6-month follow-up.Semantic proximity Read ↗

Interleukin-36 receptor antagonist deficiency patient with a novel mutation.Semantic proximity Read ↗

Clinical advances in biological therapy for generalized pustular psoriasis: a review.Semantic proximity Read ↗

Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations.Semantic proximity Read ↗

Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): A review of the literature.Semantic proximity Read ↗

The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist.Semantic proximity Read ↗

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.Semantic proximity Read ↗

IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasisSemantic proximity Read ↗

Pathophysiology of generalized pustular psoriasis.Semantic proximity Read ↗

Novel IL36RN Mutation Identified in Pediatric-Onset Generalized Pustular Psoriasis Causes IL36 Antagonist DegradationSemantic proximity Read ↗

An update on genetic basis of generalized pustular psoriasis (Review).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.